| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787584 | Journal of Thoracic Oncology | 2018 | 15 Pages |
Abstract
Nivolumab and pembrolizumab can be safe and effective among patients with NSCLC and HIV. Larger studies will be needed to determine the overall safety and efficacy of immune checkpoint inhibitors among cancer patients with HIV.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Lorena MD, Jennifer MD, Giulia C. MD, Anika E. BS, Safiya J. BA, MPH, Christine A. BA, Deepa MD, Mark S. MD, Kartik MBBS, Meghan MD, Paul A. MD, PhD, Matthew P. MD, Francisco M. MD, Sarah P. MD, Daniel B. MD, PhD, Mark M. MD, PhD,